Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Inclusion Criteria:

• Newly diagnosed aggressive lymphoma or CLL/small lymphocytic lymphoma (SLL) thatmeets disease specific criteria below:

• Study 1 - Aggressive lymphoma

• Newly diagnosed de-novo DLBCL or primary mediastinal B-cell lymphoma that willbe treated with an anthracycline-containing regimen (rituximab-cyclophosphamide, doxorubicin hydrochloride, prednisone [R-CHOP] orequivalent); patients with composite lymphomas can also be enrolled as long asthey have large cell component and will be treated with an anthracycline; inaddition, patients with "B cell lymphoma, unclassifiable, with featuresintermediate between diffuse large B cell lymphoma and Burkitt lymphoma" orpost-transplant DLBCL are also eligible as long as they meet other criteria;patients with typical Burkitt lymphoma are not eligible

• NOTE: patients can be enrolled up through day 1 of cycle 3 of therapy; thepatient is permitted to participate in any other therapeutic therapy fortheir disease as long as it does not concern vitamin D; patients can begintheir chemotherapy while awaiting vitamin D results and treatment armassignment or

• Newly diagnosed untreated peripheral T-cell non-Hodgkin lymphoma (NHL) thatwill be treated with chemotherapy; NOTE: patients can be enrolled up throughday 1 of cycle 3 of therapy; this includes the following disease types:

• Peripheral T cell lymphoma, unspecified

• Anaplastic large cell lymphoma (T and null cell type)

• Extranodal NK/T-cell lymphoma, nasal type

• Enteropathy-type T-cell lymphoma

• Hepatosplenic T-cell lymphoma

• Subcutaneous panniculitis-like T-cell lymphoma

• Angioimmunoblastic T-cell lymphoma

• Anaplastic large cell lymphoma - primary cutaneous type and

• Willing to provide tissue for correlative research purposes

• Study 2 - CLL/SLL

• Newly diagnosed (< 12 months from pre-registration on this study) CLL accordingto the National Cancer Institute (NCI) criteria or SLL according to the WorldHealth Organization (WHO) criteria; this includes previous documentation of:

• Biopsy-proven small lymphocytic lymphoma

• Diagnosis of CLL according to NCI working group criteria as evidenced byall of the following:

• Peripheral blood lymphocyte count of > 5,000/mm^3; if present,prolymphocytes should be < 55%

• Immunophenotyping consistent with CLL defined as:

• The predominant population of lymphocytes share both B-cellantigens (cluster of differentiation [CD]19, CD20, or CD23) aswell as CD5 in the absence of other pan-T-cell markers (CD3,CD2, etc.)

• Dim surface immunoglobulin expression

• Restricted surface kappa or lambda light chain expression

• Before diagnosing CLL or SLL, mantle cell lymphoma must be excludedby demonstrating a negative fluorescent in situ hybridization (FISH)analysis for t(11;14)(immunoglobulin H [IgH]/cyclin D 1 [CCND1]) onperipheral blood or tissue biopsy or negative immunohistochemicalstains for cyclin D1 on involved tissue biopsy

• Rai stage 0 or 1

• Previously untreated

• Asymptomatic with the plan for observation

• Life expectancy of at least 24 months

• Willing to provide tissue for correlative research purposes

• Both Studies:

• Capable of swallowing intact study medication capsules

• Serum calcium < 11 mg/dL; note: patients with hypercalcemia can be enrolled afterthe calcium is corrected with standard of care treatments

• Willing to return to enrolling institution for follow-up (during the activemonitoring phase of the study)

• Note: During the Active Monitoring Phase of a study (i.e., active treatment andobservation), participants must be willing to return to the consentinginstitution for follow-up

• Willing to provide blood samples for correlative research purposes

• Vitamin D level (25 hydroxy D2 + hydroxyl D3) confirmed by central laboratory review

Exclusion Criteria:

• Patients with Burkitt lymphoma or any patient receiving rituximab-cyclophosphamide,vincristine, doxorubicin, high-dose methotrexate / ifosfamide, etoposide, high-dosecytarabine (R- CODOXM/IVAC)

• Patients who previously had indolent lymphoma and now at a separate episode havelarge cell NHL (i.e. transformation